NCT05270525View on ClinicalTrials.gov

Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
COPD
Interventions
DRUG

Ensifentrine

Ensifentrine twice daily administered with jet nebulizer for 8 weeks

DRUG

Placebo

Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks

Trial Locations (2)

35205

RECRUITING

University of Alabama at Birmingham, Birmingham

48109

RECRUITING

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

lead

Verona Pharma plc

INDUSTRY